Background Falls in older adults with cancer are common, yet factors associated with fall-risk are not well-defined and may differ from the general geriatric population. This study aims to develop and validate a model of factors associated with prior falls among older adults with cancer. Methods In this cross-sectional secondary analysis, two cohorts of patients aged ≥ 65 with cancer were examined to develop and validate a model of factors associated with falls in the prior 6 months. Potential independent variables, including demographic and laboratory data and a geriatric assessment (encompassing comorbidities, functional status, physical performance, medications, and psychosocial status), were identified. A multivariate model was developed in the derivation cohort using an exhaustive modeling approach. The model selected for validation offered a low Akaike Information Criteria value and included dichotomized variables for ease of clinical use. This model was then applied in the validation cohort. Results The development cohort (N = 498) had a mean age of 73 (range 65-91). Nearly one-fifth (18.2%) reported a fall in the prior 6 months. The selected model comprised nine variables involving functional status, objective physical performance, depression, medications, and renal function. The AUC of the model was 0.72 (95% confidence intervals 0.65-0.78). In the validation cohort (N = 250), the prevalence of prior falls was 23.6%. The AUC of the model in the validation cohort was 0.62 (95% confidence intervals 0.51-0.71). Conclusion In this study, we developed and validated a model of factors associated with prior falls in older adults with cancer. Future study is needed to examine the utility of such a model in prospectively predicting incident falls.
Introduction
Falls are a common, costly, and serious event in the lives of older adults. In the general population, one-in-three older adults fall each year [1] . The CDC estimates that, in the USA, the direct annual healthcare cost of falls was $30 billion in 2010 and is expected to reach $54.9 billion by 2020 [2] . The consequences of falls are manifold: falls may result in severe injuries, including fractures and intracranial hemorrhage, nursing home placement, functional decline, and fear-of-falling [3] [4] [5] . Older adults with cancer are at greater risk of serious injuries related to falls than matched controls without cancer [6] . Further, falls are associated with increased risk of death and lower quality of life. [7, 8] In older adults with cancer, falls are associated with increased risk of toxicity of chemotherapy [9] . Functional decline subsequent to a fall may make an older patient less able to tolerate subsequent cancer therapy.
Falls are preventable [10] . Because of the great risk and cost of falls in older adults with cancer, it is imperative that we understand what factors are associated with falls and identify individuals at greater risk for incident falls. Results have been inconsistent across studies, with some studies identifying no factors predictive of falls and others finding no association with factors considered strongly predictive of falls in noncancer populations. These inconsistencies are likely due to different populations studied, varying definitions of falls used, and differing methods of fall ascertainment [11] [12] [13] [14] [15] . Reliable identification of individuals at greater risk for falls will allow targeted intervention to ultimately prevent falls in this vulnerable population.
In this study, we sought to develop and validate a model of factors associated with a higher likelihood of prior falls in the last 6 months in a cohort of older adults with cancer who underwent geriatric assessment prior to initiation of chemotherapy.
Methods
This cross-sectional study is a secondary analysis of baseline data from a previously published, IRB approved, prospective cohort study which aimed to develop and validate a predictive model of chemotherapy toxicity in older adults [16, 17] . Eligible patients were age 65 or older, with a diagnosis of cancer, who were to begin, but had not yet begun, a new course of chemotherapy. Five hundred patients participated in the development cohort in the initial study (enrolled 2006-2009) , and 250 participated in the validation cohort in the initial study (enrolled 2008-2012) . The development cohort in the chemotherapy toxicity study was used as the development cohort in this analysis [9] , and the initial validation cohort was used as the validation cohort in this analysis [17] .
Participants completed a baseline geriatric assessment [9] , including a self-report of prior falls in the past 6 months, before initiation of a new course of chemotherapy. Cases were excluded if they were missing data on falls.
Clinical data available included demographics, laboratory values, cancer type, stage, and receipt of prior chemotherapy. The geriatric assessment included an assessment of performance status (both self-reported and clinician-reported), functional status, comorbidities, medications, social support, psychological state, cognition, and hearing/visual impairment. Medications were categorized by the number of prescription and nonprescription medications as well as the specific classes of drugs. Participants were asked if they had fallen in the 6 months prior to assessment, and, if so, how many times. Data on fall-related injuries or healthcare utilization (e.g., emergency department visits) were not available.
The primary outcome was self-reported falls in the 6 months prior to assessment. It was dichotomized into a yes/no variable and logistic regression was used for analysis. Independent variables examined included demographics, cancer type and stage, prior chemotherapy, hemoglobin, creatinine clearance, and all geriatric assessment parameters. For model selection, R glmulti package with exhaustive modeling approach was used to select the best set of independent variables with the best model fitting. [18] An exhaustive modeling approach fits models for every combination of all terms, from smallest (one term versus the outcome) to the largest (all terms included). The Akaike's information criterion (AIC) and residual were calculated for each potential model. The five best models with lowest AIC and residual were selected. All five models were similarly low in terms of AIC and residual; we chose the model with the fewest variables to move forward. Once the model variables were selected, cut-points for the continuous variables were selected using the Standardized Wilcoxon statistic to ease clinical comprehension and utility of the model. A point scale was developed based on the z statistic for each variable in the final model and rounded up to the nearest integer. The Cancer and Aging Research Group fall score was created by summing up all the points. The area under the curve (AUC) was calculated to determine the discrimination of the model. Calibration was examined by comparing between the observed rate of prior falls versus expected rate of prior falls as estimated by the model for each fall score. Youden index was used to select the best cutoff point for fall score with the highest sensitivity and specificity in classifying the presence or absence of prior falls.
The model derived from the development cohort was then applied to the validation cohort. The fall scores were calculated using the same scoring system. As in the development cohort, the AUC of the model was determined and calibration in the validation set was examined by comparing the observed versus expected rate of prior falls for each fall score. R and SAS 9.3 (SAS institute, Cary, NC) were used for data analysis.
Results
In the development cohort, two participants in the original 500 patient cohort were not evaluable due to missing data on falls, resulting in a cohort of 498 patients. Table 1 presents the baseline data of the patients in the development cohort. In the development cohort, the prevalence of falls in the 6 months prior to assessment was 18.2%. Among those with falls, there were 59 patients who reported 1 fall (11.8%), 13 patients who reported 2 falls (2.6%), and 19 patients who reported 3 falls (3.8%).
The relationship between prior falls and baseline demographic, geriatric assessment, and laboratory characteristics were examined on univariate analysis ( Table 2 ). Factors significantly associated with prior falls comprised a number of variables in different domains, including functional status, comorbidities, medications and laboratory data. Exhaustive modeling of candidate independent variables resulted in 8 potential models (Supplementary Table) . The best model selected to move forward contained nine variables: (1) any dependence in instrumental activities of daily living [IADLs]), (2) slower objective physical performance (Timed Up and Go test > 13.5 s), (3) polypharmacy (≥ 4 medications), (4) creatinine clearance <30 ml/min), (5) depressed mood (Hospital Anxiety and Depression scale ≥ 8,) (6) selective serotonin reuptake inhibitor (SSRI) use, (7) benzodiazepine use, (8) proton pump inhibitor (PPI) use, and (9) self-report of BI feel like I am slowed down.^The discrimination of the model was fair, with an AUC of 0.72 (95% confidence intervals 0.65-0.78). Scores were assigned to each variable as described in the statistical section and presented in Table 3 . The fall score was then calculated as the sum of each individual score. The median fall score was 4, ranged from 0 to15 in the development cohort. Comparing to patients with a fall score of 6 or under, those with fall scores 7 or above were 4 times more likely to report falls in the past 6 months (OR 3.86, 95%CI 2.21-6.74, p < 0.001).
The model was then applied to the validation cohort. In the validation cohort, all 250 patients were evaluable. Baseline characteristics of the validation cohort are provided in Table 1 . The prevalence of prior falls in the validation cohort was 23.6%, with 15.6% reporting one fall, 4.8% reporting 2 falls, and 3.2% reporting 3 or more falls. The fall score was calculated using the same scoring system as the development cohort. The median fall score was 5 (range 0-16). For the validation cohort, the AUC of the model was 0.62 (95% confidence intervals 0.51-0.71). Figure 1 demonstrates the calibration plots of the observed prevalence of prior falls versus the expected rate of prior falls associated with the fall score in the development and validation cohorts. Comparing to patients with a fall score of 6 or under, those with fall scores 7 or above were two times more likely to report falls in the past 6 months (OR = 2.34, 95%CI 1.21-4.59, p = 0.01).
Discussion
In this study, we developed and validated a model of factors associated with prior falls within the last 6 months in older adults with cancer. Because prior falls are strongly predictive of future falls [19, 20] , with prospective validation, this model may inform approaches to assessing fall-risk that can be employed clinically to determine which older adults with cancer are at greater risk for incident falls, rather than waiting for them to have their first fall and then reacting. Identification of patients at higher risk is essential, as falls are potentially preventable through fall-prevention interventions, particularly when targeted to those at higher risk [10] .
The factors associated with prior falls in our model have face validity, based on associations seen in other studies of older adults with cancer or in general geriatric populations. For example, the need for assistance with IADLs is strongly associated with falls both in community-dwelling older adults and in older adults with cancer [12, 21] . The report of feeling Bslowed down^was also associated with prior falls in our model. Interestingly, this association was independent of both depression, antidepressant use, and slow performance on the Timed Up and Go test. Hence, the feeling of being Bslowed down^is possibly more reflective of fatigue, which has been associated with falls [13] . Self-reported slowing is also reported as a component of phenotypic frailty [22] , which is associated with a greater than twofold increased risk of falls in community-dwelling older adults without cancer [23] . Symptoms of depression are associated with prior falls in our model, as seen in other studies of community-dwelling older adults [24] . Of note, use of antidepressants was also significant in our model, independent of symptoms of depression. Others have found SSRI use to be associated with falls [25, 26] , even after controlling for residual symptoms of [25] . The mechanism for this association is not well-understood; however, one study suggested an association between paroxetine use and impaired balance which, hence, increased the risk of falls [27] . Several other medications, in addition to antidepressants, were associated with prior falls in our study, including benzodiazepines and proton pump inhibitors. Benzodiazepines are well-established to be considered potentially inappropriate in older adults [28] . They are strongly associated with falls [29, 30] in a dosedependent manner [31] . We also found an association between proton pump inhibitor (PPI) use and prior falls. Literature is emerging regarding an association between PPI use and falls, with proposed potential mechanisms related to altered calcium homeostasis or impaired B12 absorption with long-term PPI use [32] . Lastly, we found that the use of four or more medications was associated with prior falls, as has been seen in other populations [33] . Polypharmacy is extremely common in older adults with cancer, with 85% of patients in one cohort taking five or more medications [34] . Turner et al. found a statistical cut point of 5.5 medications to be associated with repeated falls [35] . Others have found the impact of polypharmacy on fall-risk to be greatest in the presence of benzodiazepines or antidepressants [36] .
Impaired renal function was associated with prior falls in our study, an association noted in populations without cancer [37] . Potential explanations for a mechanism of the association could be related to altered Vitamin D metabolism, with impaired conversion of 25-hydoxy vitamin D to 1,25 dihydroxy vitamin D [37] . Alternate potential explanations for the association between falls and impaired renal function include muscle weakness associated with chronic kidney disease [38] , increased risk of adverse drug reactions [39] , or supratherapeutic drug levels [40] , which are areas to explore in future research.
Finally, slowed performance on the Timed Up and Go (TUG) was associated with prior falls in our study; measures of physical performance have been associated with falls in other studies of populations with cancer [41] . Some studies of community-dwelling older adults suggest that alternate tests, such as gait speed, may have greater utility, and that the TUG should not be used in isolation for predicting fall-risk [42] . Indeed, in our study, the TUG was only one of nine factors comprising the fall score, supporting the multifactorial nature of falls that physical function alone does not entirely encompass.
Strengths of our study include a large, diverse cohort of older adults with multiple types of malignancy, allowing application to a broad population of older adults with cancer. In addition, the model was developed and validated in separate populations, supporting its generalizability. We used advanced statistical techniques to create a robust, generalizable, clinically useful model of the likelihood of prior falls. While the AUC of the model was lower in the validation cohort than in the development cohort, the decrement in the AUC related to the optimism of the model in the development cohort is on par with that seen in simulation models using bootstrapping in development and validation cohorts [43] .
Nonetheless, this study has several limitations. First, the cross-sectional design does not allow for prospective assessment of incident falls and their relationship with baseline factors. Retrospective recall of falls has been shown to be unreliable, resulting in misclassification bias. Consensus groups have recommended that, optimally, a primary outcome of falls should be ascertained prospectively, grounded with a validated definition of falls to limit subjectivity in participants' appraisal of what events constitute a fall [44] . Recall bias may result in differential reporting of prior falls and spurious associations.
Second, the cross-sectional design only allows us to identify factors associated with prior falls, rather than factors prospectively predictive of incident falls; it is possible that some of the associations actually resulted from the prior fall, such as slowed gait speed or increased symptoms of depression. It is unknown how this model, prospectively applied, will compare with other approaches to fall-risk prediction. Finally, the available data did not allow us to explore some candidate factors associated with falls in other studies of older adults with cancer, such as pain, brain metastases or prior falls. [31] We are also unable to explore consequences of falls, such as whether falls resulted in injury. Finally, the AUC of the model in the validation set was only fair, at 0.62, with 95% confidence intervals of 0.51-0.71, the lower bound approaching chance. Unfortunately, this highlights global limitations in our ability to predict falls in older adults, as model of falls in communitydwelling older adults using commonly used predictors, including prior falls, gait speed, and the Short Physical Performance Battery, have AUCs of 0.57-0.59 [45] . A prospective study to validate the CARG fall score and explore time-varying predictors is underway [NCT02912273] .
Another limitation is that factors that may be associated with falls in older adults with cancer, particularly peripheral neuropathy, sarcopenia, or brain metastases, are not available in our dataset. For example, data on the presence of preexisting neuropathy or chemotherapy-induce peripheral neuropathy for those receiving second or subsequent lines of therapy are not available. Peripheral neuropathy is a wellestablished risk factor for falls in older adults with cancer [46] [47] [48] [49] . Similarly, we have data on neither the presence of sarcopenia, which is associated with falls in communitydwelling older adults [50] , nor the presence of brain metastases, which was associated with falls in older adults with advanced cancer [31] .
In conclusion, the Cancer and Aging Research Group fall score provides insight into factors associated with prior falls in older adults with cancer. The factors associated with prior falls in our study include functional dependence, self-reported slowing, depression, use of SSRIs, benzodiazepines or PPIs, polypharmacy (i.e., use of ≥ 4 medications), impaired physical performance on the TUG and impaired renal function. In the future, we anticipate that more robust models will be developed and validated, incorporating the factors we have identified, along with other potentially relevant factors such as chemotherapy-induced peripheral neuropathy, brain metastases, and other cancer-specific variables, to improve our ability to identify older adults with cancer at increased risk for falls in order to intervene and prevent falls.
